Skip to main content

Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026

Remote Patient Monitoring Market

The Remote Patient Monitoring (RPM) market is projected to grow from USD 10.0 billion in 2025 to USD 18.8 billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.5%. This expansion is driven by the increasing prevalence of chronic diseases, aging populations, and the global shift toward preventive and home-based healthcare solutions. RPM technologies enable continuous, real-time monitoring of patients outside traditional clinical settings, improving outcomes and reducing healthcare costs.

Key segments include cardiac, neurological, respiratory, and multiparameter monitoring devices, with applications spanning hospitals, ambulances, and homecare environments.

Report scope & segmentation

Remote Patient Monitoring Market By type (Cardiac Monitoring Devices, Neurological Monitoring Devices, Respiratory Monitoring Devices, Multiparameter Monitoring Devices), and by Application, and by Region, Global trends and forecast from 2026 to 2035

Market size

Growth trajectory through 2035

$10.00 Bn Base 2025
↑ 6.50% CAGR 2025–2035
$18.77 Bn Forecast 2035

Remote Patient Monitoring Market · Market size 2025–2035

Base year 2025 · Forecast 2035 · USD Billion

Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.

What this shows

The Remote Patient Monitoring Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.

What's new in this edition

Here's what changed

This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.

Recent developments tracked

  1. Development 01 AI Integration in RPM Devices
    • Recent advancements in artificial intelligence are transforming RPM devices, enabling real-time data analysis and predictive insights. Companies such as Philips and GE Healthcare are integrating AI-driven analytics into their monitoring platforms to enhance diagnostic accuracy and patient outcomes.
  2. 2025 Regulatory Approvals
    • The FDA and other regulatory bodies have approved several new RPM devices in 2025, including wearable cardiac monitors and remote glucose tracking systems. These approvals are expected to accelerate market adoption and drive innovation.
  3. Development 03 Partnerships for Remote Care
    • Strategic collaborations between RPM providers and telehealth platforms are creating integrated solutions for remote patient management. For example, partnerships between Medtronic and telehealth companies are enabling seamless data sharing and care coordination.
  4. Development 04 Expansion in Chronic Disease Management
    • Companies are developing specialized RPM solutions for chronic conditions such as diabetes, cardiovascular diseases, and respiratory disorders. These tailored devices are improving patient outcomes and reducing healthcare costs.

Emerging opportunities added

  • Expansion in Emerging Markets Rapid urbanization and increasing healthcare expenditure in regions such as Asia-Pacific and Latin America present significant growth opportunities. Rising awareness of preventive care and improving healthcare infrastructure are driving demand for RPM solutions in these markets.
  • Integration with AI and Big Data The convergence of RPM with artificial intelligence and big data analytics offers opportunities to enhance diagnostic accuracy and predictive capabilities. AI-driven insights can enable personalized treatment plans and early intervention strategies.
  • Partnerships and Collaborations Collaborations between technology providers, healthcare institutions, and payers can accelerate innovation and market penetration. Strategic partnerships can address gaps in device development, data management, and reimbursement frameworks.
  • Focus on Chronic Disease Management The growing burden of chronic diseases presents opportunities for RPM solutions tailored to specific conditions, such as diabetes, cardiovascular diseases, and respiratory disorders. Specialized devices and platforms can improve patient outcomes and reduce healthcare costs.

Executive snapshot

The four things that matter

A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.

Market size · 2025–2035

$18.77 Bn

forecast for 2035

2025 base
$10.00 Bn
CAGR
6.50%
Expansion
1.9×

Market shape

Cardiac Monitoring Devices

top segment · 40.7% share

Leading region
North America
Top-5 concentration
Low to medium · ~42%

Forces at play

Aging Population and Chronic Disease Prevalence

▲ top tailwind

▼ headwind
Regulatory Hurdles
Named players
15 profiled
Growth peak
2027–2031

Latest development

Latest tracked

AI Integration in RPM Devices: Recent advancements in artificial intelligence are transforming RPM devices, enabling real-time data analysis and predictive insights. Companies such as Philips and GE Healthcare are integrating AI-driven analytics into their monitoring platforms to enhance diagnostic accuracy and patient outcomes

+4 more tracked in this edition

Report scope

What this report answers

The specific decisions and questions covered in the 139-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.

  • How big is the Remote Patient Monitoring Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
  • Which of holds the largest share, and how do the growth rates diverge?
  • How is demand distributed across patient monitoring and post, discharge follow, growing segment, driven by the demand for remote monitoring solutions. Homecare applications, and which application is scaling fastest?
  • How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
  • Where do Cardinal Health, Owens & Minor, Henry Schein Inc and 12 other named players sit in market share, tier, and product breadth?
  • What are the top growth drivers (led by Aging Population and Chronic Disease Prevalence) and top restraints (led by Regulatory Hurdles), with quantified CAGR impact?
  • What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
  • Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?

Market dynamics

Why the number moves this way

The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.

Growth drivers

Pulling the market up

  • Aging Population and Chronic Disease Prevalence The global rise in chronic conditions such as hypertension, diabetes, and cardiovascular diseases is driving demand for continuous monitoring solutions. Aging populations require ongoing health management, which RPM technologies facilitate through real-time data collection and remote interventions.
  • Shift Toward Preventive Healthcare Governments and healthcare organizations are prioritizing early detection and management of diseases to reduce costs and improve patient outcomes. RPM devices enable proactive health monitoring, reducing the need for episodic care and hospitalizations.
  • Technological Advancements Innovations in wearable sensors, AI-driven analytics, and connectivity are enhancing the accuracy and usability of RPM devices. These advancements improve diagnostic capabilities and enable seamless integration with healthcare systems.
  • Regulatory Support and Reimbursement Policies Favorable regulatory frameworks and reimbursement policies are encouraging the adoption of RPM technologies. Supportive policies reduce financial barriers for healthcare providers and patients, accelerating market growth.
  • Increased Demand for Home Healthcare The preference for home-based care solutions is rising due to convenience and cost-effectiveness. RPM devices enable patients to manage their health remotely, reducing the burden on healthcare facilities and improving accessibility.

Restraints

Holding it back

  • Regulatory Hurdles Approval timelines for RPM devices can extend by 6–12 months post-2025, delaying market entry for new technologies. Stringent regulatory requirements for safety and efficacy add complexity to the development and commercialization process.
  • Data Privacy and Security Concerns The transmission and storage of sensitive health data raise concerns about cybersecurity and patient privacy. Compliance with data protection regulations, such as HIPAA, requires robust infrastructure and ongoing investment.
  • High Implementation Costs The initial costs of deploying RPM systems, including device procurement, software integration, and staff training, can be prohibitive for smaller healthcare providers. These costs may limit adoption in resource-constrained settings.
  • Interoperability Challenges RPM devices often operate on disparate platforms, creating integration challenges with existing electronic health records (EHR) systems. Lack of standardization hinders seamless data sharing and workflow efficiency.
  • Patient Adoption Barriers Some patients, particularly older adults, may face challenges in adopting RPM technologies due to limited digital literacy or resistance to change. Education and user-friendly design are critical to overcoming these barriers.

Impact analysis

Quantified drivers & restraints

Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.

Driver% Impact on CAGRGeographic RelevanceImpact Timeline
Aging Population and Chronic Disease Prevalence +2.9% Global 2025–2035
Shift Toward Preventive Healthcare +1.8% Global 2025–2035
Technological Advancements +1.4% Global 2025–2035
Regulatory Support and Reimbursement Policies +1.0% Global 2025–2035

Restraints impact analysis

Restraint% Impact on CAGRGeographic RelevanceImpact Timeline
Regulatory Hurdles −1.2% Global 2025–2029
Data Privacy and Security Concerns −0.8% Global 2025–2029
High Implementation Costs −0.6% Global 2025–2029

The Remote Patient Monitoring (RPM) market is segmented by type and application, reflecting the diverse needs of healthcare providers and patients.

Revenue share by type · 2025 base year

% OF $10.00 BN REMOTE PATIENT MONITORING MARKET · 4 TYPES COVERED

Each slice = that type's share of the total $10.00 Bn Remote Patient Monitoring Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.

By type

By application

  1. patient monitoring and post

  2. discharge follow

  3. growing segment, driven by the demand for remote monitoring solutions. Homecare

  4. chart

  5. template="treemap" data

  6. palette="dual_tone_teal">

  7. size="15" fill="#0f172a" text

  8. anchor="middle" font

Geography

Regional market share

Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.

Regional share · 2025

SHARE OF $10.00 BN BASE MARKET

Bars sized to relative regional share. Leader region highlighted in gold.

What this shows

North America leads regional demand at ~41.4% in 2025. Driven by manufacturing scale and end-market density.

Competitive landscape

Who's competing, and how

The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.

The Remote Patient Monitoring (RPM) market is highly competitive, with a mix of established medical technology firms and innovative startups vying for market share. Key players are focusing on product differentiation, strategic partnerships, and geographic expansion to strengthen their positions.

Concentration snapshot

Top 5 players control ~35–50% of the market

Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.

Top 5 players Rest of market
~43%
~58%

Competitive tiers

Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.

Tier 1 · Leaders

3companies

Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.

Tier 2 · Challengers

5companies

Regional strongholds, focused portfolio, actively expanding via M&A or capacity.

Tier 3 · Emerging

7companies

Niche or early-stage, differentiated technology or early-mover positioning.

Named players covered

Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.

  • Cardinal Health

    Leading player · Full profile in the report

    Rank 01
    Share est. ~16%
    Revenue $■■■M
    HQ ■■■
  • Owens & Minor

    Profiled · Full detail in the report

    Rank 02
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Henry Schein Inc

    Profiled · Full detail in the report

    Rank 03
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • 3M Health Care

    Profiled · Full detail in the report

    Rank 04
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Kimberly-Clark Health Care

    Profiled · Full detail in the report

    Rank 05
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Molnlycke Health Care

    Profiled · Full detail in the report

    Rank 06
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Smith & Nephew plc

    Profiled · Full detail in the report

    Rank 07
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • ConvaTec Group plc

    Profiled · Full detail in the report

    Rank 08
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■

+ 7 more player profiles in the full report.

Unlock the full competitive landscape

Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.

Download sample

Regulatory landscape

Policy and standards affecting the forecast

Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.

  1. United States

    FDA · IRA drug pricing · CMS

    FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.

  2. European Union

    EMA · HTA Reg · GDPR-health

    EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.

  3. China / APAC

    NMPA · VBP · NRDL

    NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.

  4. Global standards

    ICH · WHO · Pharmacopoeia

    ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.

Purchase options

License this report

All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.

Individual

Single user

$3,499

  • 1 named user, non-transferable
  • Full PDF + Excel data pack
  • 1 hour analyst clarification call
Buy Now Request sample
Enterprise

Corporate

$5,499

  • Unlimited users org-wide
  • Full PDF + Excel data pack
  • 4 hours analyst time
  • Presentation-ready deck
Buy Now Request sample

Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.

How buying works

  1. 01 Select a license — your enquiry reaches the desk lead within one business day.
  2. 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
  3. 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.

Payment methods accepted

  • PayPalGlobal
  • RazorpayCards · UPI · Netbanking
  • Visa · Mastercard · AmexVia gateway
  • Wire transferUSD · EUR · INR · GBP
  • Corporate PONet-30 on approval

Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.

Methodology

How we built this estimate

Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.

  1. Primary research

    Interviews · surveys

    Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.

  2. Secondary research

    Filings · associations · databases

    Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.

  3. Data triangulation

    Three independent paths

    Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.

  4. Analyst review

    Senior sign-off

    Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.

Frequently asked questions

Common questions about this report

  • How big is the Remote Patient Monitoring Market in 2025?

    The Remote Patient Monitoring Market is estimated at approximately $10.00 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.

  • What's the forecast growth rate through 2035?

    The market is projected to grow at a 6.50% CAGR from 2025 to 2035, reaching $18.77 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.

  • Which region leads the market?

    North America leads the market, accounting for approximately 41.4% of 2025 revenue. Country-level detail is broken out in the report.

  • Which segment leads the market?

    Cardiac Monitoring Devices leads the type segmentation with an estimated 40.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.

  • Who are the major players covered?

    The report profiles 15 named players including Cardinal Health, Owens & Minor, Henry Schein Inc, 3M Health Care, Kimberly-Clark Health Care, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.

  • What's driving growth in this market?

    The top growth driver is Aging Population and Chronic Disease Prevalence. The global rise in chronic conditions such as hypertension, diabetes, and cardiovascular diseases is driving demand for continuous monitoring solutions. Aging populations require ongoing health management, which RPM technologies facilitate through real-time data collection and remote interventions.

  • What are the main restraints?

    The primary restraint is Regulatory Hurdles. Approval timelines for RPM devices can extend by 6–12 months post-2025, delaying market entry for new technologies. Stringent regulatory requirements for safety and efficacy add complexity to the development and commercialization process.

  • What are the most recent developments?

    Recent notable events include: : AI Integration in RPM Devices: Recent advancements in artificial intelligence are transforming RPM devices, enabling real-time data analysis and predictive insights. Companies such as Philips and GE Healthcare are integrating AI-driven analytics into their monitoring platforms to enhance diagnostic accuracy and patient outcomes; 2025: Regulatory Approvals: The FDA and other regulatory bodies have approved several new RPM devices in 2025, including wearable cardiac monitors and remote glucose tracking systems. These approvals are expected to accelerate market adoption and drive innovation; : Partnerships for Remote Care: Strategic collaborations between RPM providers and telehealth platforms are creating integrated solutions for remote patient management. For example, partnerships between Medtronic and telehealth companies are enabling seamless data sharing and care coordination. Full timeline in the report.

  • Can I customise the scope?

    Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.